Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi Out-licenses Middle East/North African Rights for PD-1 to Hikma Pharma

publication date: Dec 28, 2022

Shanghai Junshi Biosciences out-licensed Middle East/North African rights to its lead drug, the anti-PD-1 toripalimab, to Hikma Pharma, a specialist in the region. Hikma will also have the right of first negotiation in three other Junshi candidates still in development. In China, toripalimab is approved for six indications, and Junshi is currently conducting global trials of the drug in cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin. Financial details of the agreement were not disclosed. More details....

Stock Symbol: (HK: 1877; SHA: 688180)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital